EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Avacincaptad pegol, the second approved aptamer medicine – A mini review

Miklós Bege, Rasha Ghanem Kattoub, Anikó Borbás

De Remediis · 2025

DOI: 10.71116/8n3dc940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift De Remediis, 2025. Verfasst von Miklós Bege und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic oligonucleotides are employed in the treatment of a variety of diseases, primarily functioning through mechanisms associated with gene silencing technologies. In contrast, aptamers exhibit mechanisms of action that are more akin to those of protein-based monoclonal antibodies. However, owing to their oligonucleotide structure, aptamers possess several advantages over antibodies. Despite these benefits, the adoption of aptamers in clinical medicine has not reached the levels observed with monoclonal antibodies or gene-silencing oligonucleotides. Almost two decades after the approval of pegaptanib, the first approved aptameric therapeutic for the treatment of neovascular AMD (age-related macular degeneration), a second aptamer has recently received approval to treat geographic atrophy, an advanced form of AMD. In this review, we aim to provide an overview of the pharmacology and chemistry of avacincaptad pegol, the second approved aptameric drug.

Zitieren

APA

Bege, M., Kattoub, R. G., & Borbás, A. (2025). Avacincaptad pegol, the second approved aptamer medicine – A mini review. De Remediis. https://doi.org/10.71116/8n3dc940

Vancouver

Bege M, Kattoub RG, Borbás A. Avacincaptad pegol, the second approved aptamer medicine – A mini review. De Remediis. 2025. doi:10.71116/8n3dc940

BibTeX
@article{Bege2025,
  author = {Bege, Miklós and Kattoub, Rasha Ghanem and Borbás, Anikó},
  title = {Avacincaptad pegol, the second approved aptamer medicine – A mini review},
  journal = {De Remediis},
  year = {2025},
  doi = {10.71116/8n3dc940}
}
Kostenlos starten →